Study S000883

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04657939
Acronym: Lean-DM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 57
Start: 2020-12-01
Primary completion: 2022-10-31
Lead sponsor: University of Leeds
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Liraglutide; DRUG:Pioglitazone
Results posted: FALSE
Secondary identifiers: OTHER_GRANT:18/0005908; OTHER:19/WM/0365

Registered primary outcomes

Change in myocardial perfusion after treatment [40 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008914	Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. Chowdhary A, Journal of the American College of Cardiology	2024	Randomized trial	PMID 39084829 DOI	cites ClinicalTrials.gov:NCT04657939; registry reference DERIVED:39084829